118 results
424B3
QNRX
Quoin Pharmaceuticals Ltd
10 May 24
Prospectus supplement
4:10pm
of this positive initial data and the absence of any safety concerns from both studies, on November 8, 2023 we submitted a number of protocol amendments … safety monitoring or other studies requested by regulatory agencies;
the duration of patient follow-up;
the timing and receipt of regulatory approvals
POS AM
QNRX
Quoin Pharmaceuticals Ltd
29 Mar 24
Prospectus update (post-effective amendment)
4:11pm
to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs … product candidates may cause undesirable side effects or have other properties impacting safety that could delay or prevent their regulatory approval
8-K
EX-99.1
QNRX
Quoin Pharmaceuticals Ltd
13 Mar 24
Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results
4:52pm
a number of clinical endpoints
Eligibility age for enrollment into both studies has been lowered to fourteen years and older
No safety concerns have … a favorable impression of QRX003 across multiple assessed metrics.
No safety concerns have been reported to date for any subject in either of Quoin’s studies
424B3
5tmbzv0mmbe21u
8 Mar 24
Prospectus supplement
4:06pm
424B3
2y8j igzn83m3h
8 Mar 24
Prospectus supplement
4:04pm
8-K
EX-10.1
wobdr4c1fnt
8 Mar 24
Quoin Pharmaceuticals Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies
4:01pm
424B4
ze4lp
6 Mar 24
Prospectus supplement with pricing info
5:07pm
424B3
5zq197sz3jn00
4 Mar 24
Prospectus supplement
5:27pm
8-K
EX-99.1
jt0gptfnkg tx55
18 Dec 23
Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome
5:29pm
424B3
m92 w0r6nxub
9 Nov 23
Prospectus supplement
5:15pm
8-K
EX-99.1
p8q3641bh 5i6zz1keps
9 Nov 23
Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2023 Financial Results
5:10pm
424B3
0cpm6dbqg5xi7tcj
14 Sep 23
Prospectus supplement
4:38pm
8-K
EX-10.1
nk1w0od4k4ap81amrr5
12 Sep 23
Entry into a Material Definitive Agreement
6:01pm
424B3
5gqwokil4o8xfpmbqye
3 Aug 23
Prospectus supplement
4:51pm